Affinity Asset Advisors »

Belite Bio shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Belite Bio (BLTE) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Belite Bio

Tip: Access up to 7 years of quarterly data

All positions including Belite Bio held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Belite Bio by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2026-03-31 $10M 65k 159.44
2025-12-31 $3.2M 20k 159.96

More positions owned by Affinity Asset Advisors

State Str Spdr S&p 500 Etf T Tr Unit Put Option (SPY)
Apogee Therapeutics (APGE)
Xenon Pharmaceuticals (XENE)
Erasca (ERAS)
Insmed Com Par $.01 (INSM)
Roivant Sciences SHS (ROIV)
Spyre Therapeutics Com New (SYRE)
Centessa Pharmaceuticals Sponsored Ads
Praxis Precision Medicines I Com New (PRAX)
Anaptysbio Inc Common (ANAB)
Alkermes SHS (ALKS)
Cytokinetics Com New (CYTK)
Abivax Sa Sponsored Ads (ABVX)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Arcellx Common Stock (ACLX)

View all positions for Affinity Asset Advisors

Top funds holding Belite Bio

Darwin Global Management
Paradigm Biocapital Advisors
UBS Group
Rtw Investments
Millennium Management
Holocene Advisors
Eventide Asset Management
Deerfield Management Company
Morgan Stanley
Perceptive Advisors
Patient Square Capital
Duquesne Family Office
Goldman Sachs Group
MPM Oncology Impact Management
Affinity Asset Advisors

View all funds holding Belite Bio